PL1849470T5 - Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej - Google Patents

Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej

Info

Publication number
PL1849470T5
PL1849470T5 PL06712292.9T PL06712292T PL1849470T5 PL 1849470 T5 PL1849470 T5 PL 1849470T5 PL 06712292 T PL06712292 T PL 06712292T PL 1849470 T5 PL1849470 T5 PL 1849470T5
Authority
PL
Poland
Prior art keywords
alpha
trifluorothymidine
anticancer drug
drug containing
phosphorylase inhibitor
Prior art date
Application number
PL06712292.9T
Other languages
English (en)
Polish (pl)
Other versions
PL1849470T3 (pl
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1849470(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL1849470T3 publication Critical patent/PL1849470T3/pl
Publication of PL1849470T5 publication Critical patent/PL1849470T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06712292.9T 2005-01-26 2006-01-25 Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej PL1849470T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (2)

Publication Number Publication Date
PL1849470T3 PL1849470T3 (pl) 2017-11-30
PL1849470T5 true PL1849470T5 (pl) 2024-06-10

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06712292.9T PL1849470T5 (pl) 2005-01-26 2006-01-25 Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej

Country Status (21)

Country Link
EP (1) EP1849470B2 (member.php)
JP (1) JP5576591B2 (member.php)
KR (1) KR101468216B1 (member.php)
AU (1) AU2006209547C1 (member.php)
BE (1) BE2017C028I2 (member.php)
CA (1) CA2594713A1 (member.php)
CY (2) CY1119393T1 (member.php)
DK (1) DK1849470T4 (member.php)
ES (1) ES2630002T5 (member.php)
FI (1) FI1849470T4 (member.php)
FR (1) FR17C1028I2 (member.php)
HU (2) HUE033306T2 (member.php)
LT (2) LT1849470T (member.php)
LU (1) LUC00036I2 (member.php)
NL (1) NL300889I2 (member.php)
PL (1) PL1849470T5 (member.php)
PT (1) PT1849470T (member.php)
RU (1) RU2394581C2 (member.php)
SI (1) SI1849470T2 (member.php)
TW (1) TWI362265B (member.php)
WO (1) WO2006080327A1 (member.php)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
LT1849470T (lt) 2005-01-26 2017-07-25 Taiho Pharmaceutical Co., Ltd. Priešvėžinis vaistas, kurio sudėtyje yra alfa, alfa, alfa - trifluortimidinas ir timidinfosforilazės inhibitorius
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8536188B2 (en) * 2007-04-25 2013-09-17 Cyclacel Limited Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
DK2273983T3 (en) 2008-05-09 2016-09-19 Gruenenthal Gmbh A process for the preparation of a powdery formulation intermediate and a fixed final dosage form using a sprøjtestørkningstrin
CA2723944A1 (en) * 2008-05-15 2009-11-19 Jan Balzarini Anti-cancer combination therapy
NZ596667A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
MX2012000369A (es) 2009-07-22 2012-02-01 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion.
CN103269688A (zh) 2010-09-02 2013-08-28 格吕伦塔尔有限公司 包含无机盐的抗破碎剂型
AU2011297892B2 (en) 2010-09-02 2014-05-29 Grunenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
SMT201800108T1 (it) 2011-08-16 2018-05-02 Taiho Pharmaceutical Co Ltd Agente antitumorale e metodo di previsione dell'effetto terapeutico per pazienti con cancro colorettale con kras mutato
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI503122B (zh) 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
WO2013137284A1 (ja) 2012-03-14 2013-09-19 日清ファルマ株式会社 含硫アミノ酸含有組成物
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2849756A1 (en) * 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor
HRP20201691T1 (hr) * 2013-03-27 2020-12-25 Taiho Pharmaceutical Co., Ltd. Antitumorni agens koji uključuje irinotekan hidroklorid hidrat
UA117581C2 (uk) * 2013-03-27 2018-08-27 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний лікарський засіб, який включає низькодозований гідрохлориду іринотекану гідрат
AU2014266278B2 (en) * 2013-05-17 2017-07-13 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of TK1 protein has increased
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HRP20230523T1 (hr) 2013-09-06 2023-08-04 Taiho Pharmaceutical Co., Ltd. Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
JP6871868B2 (ja) * 2016-01-08 2021-05-19 大鵬薬品工業株式会社 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤
JP6882205B2 (ja) * 2016-02-05 2021-06-02 大鵬薬品工業株式会社 重度腎機能障害を有する癌患者に対する治療方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
US20260021045A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
PT884051E (pt) * 1996-09-24 2005-03-31 Taiho Pharmaceutical Co Ltd Inibidores de metasteses cancerosas contendo derivados de uracilo
LT1849470T (lt) 2005-01-26 2017-07-25 Taiho Pharmaceutical Co., Ltd. Priešvėžinis vaistas, kurio sudėtyje yra alfa, alfa, alfa - trifluortimidinas ir timidinfosforilazės inhibitorius

Also Published As

Publication number Publication date
TW200637562A (en) 2006-11-01
FR17C1028I1 (member.php) 2017-09-29
CY2017029I1 (el) 2018-02-14
HUS1700032I1 (hu) 2017-09-28
JP5576591B2 (ja) 2014-08-20
SI1849470T2 (sl) 2024-05-31
CA2594713A1 (en) 2006-08-03
RU2394581C2 (ru) 2010-07-20
AU2006209547B2 (en) 2011-05-26
ES2630002T3 (es) 2017-08-17
SI1849470T1 (sl) 2017-10-30
CY2017029I2 (el) 2018-02-14
TWI362265B (en) 2012-04-21
LTC1849470I2 (lt) 2019-10-25
DK1849470T4 (en) 2024-04-02
NL300889I1 (nl) 2017-08-14
AU2006209547A1 (en) 2006-08-03
FR17C1028I2 (fr) 2018-11-02
CY1119393T1 (el) 2018-02-14
DK1849470T3 (en) 2017-08-14
AU2006209547C1 (en) 2022-04-07
EP1849470A4 (en) 2010-12-08
NL300889I2 (nl) 2018-01-16
HUE033306T2 (hu) 2017-11-28
KR101468216B1 (ko) 2014-12-03
FI1849470T4 (fi) 2024-03-22
LT1849470T (lt) 2017-07-25
LUC00036I2 (member.php) 2017-12-01
KR20070104559A (ko) 2007-10-26
RU2007132181A (ru) 2009-03-10
PT1849470T (pt) 2017-09-22
LTPA2017024I1 (lt) 2017-08-10
JPWO2006080327A1 (ja) 2008-06-19
BE2017C028I2 (member.php) 2025-09-10
ES2630002T5 (es) 2024-09-19
WO2006080327A1 (ja) 2006-08-03
EP1849470B1 (en) 2017-06-21
LUC00036I1 (member.php) 2017-10-02
PL1849470T3 (pl) 2017-11-30
EP1849470A1 (en) 2007-10-31
EP1849470B2 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
SI1849470T1 (sl) Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze
SI1913001T1 (sl) (r)-n-metilnaltrekson, postopki za njega sintezo in njega farmacevtsko uporabo
SI1928882T1 (sl) (s)-n-metilnaltrekson, postopek za njega sintezo in njega farmacevtska uporaba
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
ZA200709856B (en) Fluorene derivatives,compositions containing said derivatives and the use thereof
IL194751A0 (en) Drugs and uses
PL2057153T3 (pl) POCHODNE (3-ARYLO-PIPERAZYN-1-YLOWE) 6,7-DIALKOKSYCHINAZOLINY, 6,7-DIALKOKSYFTALAZYNY i 6,7-DIALKOKSYIZOCHINOLINY
PL2034015T3 (pl) Immunostymulujący oligonukleotyd i jego zastosowanie farmaceutyczne
IL198236A0 (en) Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
AP2008004533A0 (en) Pharmaceutical combination
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
GB0516069D0 (en) Pharmaceutical and use thereof
ZA200804666B (en) Pharmaceutical combination
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
PL1791872T3 (pl) Biotynylowane heksadekasacharydy, kompozycje farmaceutyczne i ich zastosowanie
EP1915988A4 (en) COMPRESSOR COMPRISING MULTIPLE SEGMENTS CONTAINING MEDICAMENTS
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
IL177759A0 (en) Cospeptin, cosmedin and their uses
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
IL191618A0 (en) N-hydroxyamide derivatives, their preparation and use
TWI372053B (en) Combination drug
AP2008004389A0 (en) Pharmaceutical combinations containing lamivudine,stavudine,stavudine and navirapine
HK1118825A (en) Substituted oxindol-derivatives, medicaments containing said derivatives and use thereof
GB0500826D0 (en) Pharmaceutical use